Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...
FDA approves Blueprint’s GAVRETO for lung cancer Blueprint Medicines Corporation ( BPMC ) announced that the FDA has given its approval to GAVRETO for treating adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer. Blueprint is coll...
CAMBRIDGE, Mass. , Sept. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Jeff Albers , Blueprint Medicines' Chief Execut...
Under accelerated review status, the FDA approves Blueprint Medicine's (NASDAQ: BPMC ) Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). More news on: Blueprint Medicines Corporatio...
CAMBRIDGE, Mass. , Sept. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRET...
CAMBRIDGE, Mass. , Sept. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the appointment of Fouad Namouni, M.D., as President, Research ...
Blueprint Medicines Corporation (BPMC) Q2 2020 Earnings Conference Call July 30, 2020 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chief Commercial Officer Mike Landsittel - CFO Andy Boral - Chief Medical Officer Co...
Blueprint Medicines (NASDAQ: BPMC ) : Q2 GAAP EPS of -$2.28 misses by $0.15 . More news on: Blueprint Medicines Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
CAMBRIDGE, Mass. , July 30, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the second quarte...
Theratechnologies announces positive report for tesamorelin in NASH Theratechnologies Inc. ( THTX ) announced positive data corroborating the impact of tesamorelin in treating HIV-associated nonalcoholic steatohepatitis. The data has been gleaned from a sub-analysis of the Phase 2 study. T...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...